Category: clinical study retractions

Bone researcher is up to 17 retractions

A bone researcher has lost three more papers for scientific misconduct.

The new retractions bring Yoshihiro Sato’s total to 17 and put him on our Leaderboard.

According to the retraction notices, Sato asked the Journal of Neurology, Neurosurgery, and Psychiatry to retract three of his papers “due to scientific misconduct.” In the letter, Sato—who is corresponding author on all three papers—explained he included co-authors without their consent and that none of the other authors listed worked on the study or article.

In May, the editors issued expressions of concern while they investigated (1, 2, 3), and last month, the journal retracted the three articles.

Here’s the retraction notice for “Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson’s disease:” Continue reading Bone researcher is up to 17 retractions

Fertility docs said their study didn’t need ethics review. An investigation said they were wrong.

Arcispedale Santa Maria Nuova-IRCCS. Credit: IRCCS-ASMN

A journal is retracting a paper on the relative merits of one fertility procedure compared to another because the study never received ethical review or approval.

In the paper, “Intracytoplasmic morphologically selected sperm injection versus conventional intracytoplasmic sperm injection: a randomized controlled trial,” originally published Aug. 27, 2015 in Reproductive Biology and Endocrinology, the authors wrote: Continue reading Fertility docs said their study didn’t need ethics review. An investigation said they were wrong.

Rowdy Roddy Pilferer: Wrestling journal takes down plagiarized paper

A journal devoted to wrestling science — we’re not sure if it’s the only one — has given the old reverse frankensteiner to a 2016 article whose authors stole much of their text from a conference presentation one of them had reviewed for the meeting.

The article, “The Role of Goal Setting, Collectivism, and Task Orientation on Iranian Wrestling Teams Performance,” appeared in International Journal of Wrestling Science, a Taylor & Francis title. Its two authors were Hossein Abdolmaleki and Seyyed Bahador Zakizadeh, of the Islamic Azad University in Karaj, Iran.

Here’s the notice: Continue reading Rowdy Roddy Pilferer: Wrestling journal takes down plagiarized paper

Amid legal battle, psych journal issuing caution about torture paper

A psychology journal plans to issue an editor’s note about a controversial paper exploring what the author called “the biggest scandal to hit” the American Psychological Association (APA) in years.

The note cautions readers that the subject of the paper, published in the SAGE journal Teaching of Psychology, is part of a pending lawsuit, and that “teachers considering using the article in their classrooms” should watch for developments in the case.   Continue reading Amid legal battle, psych journal issuing caution about torture paper

Publisher flags paper on same-sex parenting after neo-Nazi group cites it

A publisher has issued an expression of concern (EoC) about a study that claimed children with same-sex parents were at greater risk of depression and abuse, after posters using statistics from the paper to support a homophobic message appeared in Australia and the US.

On Aug. 21, several news websites reported that these posters were appearing in Melbourne, Australia, citing claims from a 2016 paper published in Depression Research and Treatment, which said that children with same-sex parents are more at risk for depression, abuse, and obesity than children with opposite-sex parents. The poster had also appeared previously in Minneapolis and has been traced to a neo-Nazi group, as reported by HuffPost Australia. Australia is preparing for a national, non-binding, mail-in vote on whether to provide marriage equality for same-sex couples.

The EoC mechanism, which was chosen by the journal’s publisher, Hindawi, is an unusual choice here. The paper’s author, D. Paul Sullins, a sociology professor at The Catholic University of America and the paper’s author, told Retraction Watch that Hindawi contacted him Aug. 21 about the decision. Initially, he told us he didn’t have any “particular objection to it,” but later told us he changed his mind after he read more about COPE’s guidelines for EoCs: Continue reading Publisher flags paper on same-sex parenting after neo-Nazi group cites it

Updated: Ohio State revokes PhD of co-author of now-retracted paper on shooter video games

Jodi Whitaker, via University of Arizona

[This post, which at 1200 UTC 8/25/17 originally reported on the then-upcoming vote, has been updated at 1800 UTC 8/25/17 to include the results of the vote.]

A researcher who co-authored a paper about video games that was retracted earlier this year has had her PhD from The Ohio State University revoked.

As WOSU reported this afternoon, the vote today of the university’s Board of Trustees was unanimous. The scheduled vote on whether to revoke Jodi Whitaker’s degree was first reported yesterday by The Columbus Dispatch.

While a graduate student at Ohio State, Whitaker was co-author of a paper that claimed to find that first-person shooter video games improved marksmanship. As we’ve reported, the paper, published online in 2012, was retracted earlier this year, two years after a university committee was alerted to irregularities in the data by two outside researchers.

The controversy over the paper became heated at times. Continue reading Updated: Ohio State revokes PhD of co-author of now-retracted paper on shooter video games

Given “wrong pathology slides,” heart journal retracts paper

A cardiology journal has retracted a paper after the authors were unable to provide correct pathology slides to replace the wrong ones submitted with the original manuscript.

The paper is titled “Aortic Valve Endocarditis and Coronary Angiography With Cerebral Embolic Protection,” published on April 10, 2017 in The Journal of the American College of Cardiology: Cardiovascular Interventions (JACC:CI). It has not yet been cited, according to Clarivate Analytics’ Web of Science.

JACC:CI retracted the paper on Aug. 14, providing this notice: Continue reading Given “wrong pathology slides,” heart journal retracts paper

Hey, that’s my case study: Another retraction after doctors claim rights to case write-up

A group of researchers have retracted their 2016 case report about a rare dermatologic disorder in the wake of disputes about authorship and institutional approval.

The paper describes a young boy with Job’s Syndrome, in which patients experience painful, itchy and frequently disfiguring skin lesions, along with a constellation of other possible symptoms. The condition is extremely rare, occurring in less than one in 1 million births.

This isn’t the first time a journal has retracted a case study after another group of authors claimed ownership of the case. Earlier this year, we covered a retraction from a neuro-ophthalmology journal after the doctors who treated a patient suffering from a gruesome eye trauma took issue with the fact that radiologists had already published their diagnostic images as a case study.

According to the notice for this latest retraction:

Continue reading Hey, that’s my case study: Another retraction after doctors claim rights to case write-up

Released FDA docs reveal details of agency’s (failed) attempt to retract paper

Earlier this year, a raging controversy regarding a new drug spilled into the pages of a leading medical journal: the head of the U.S. Food and Drug Administration and another official publicly called for the retraction or correction of a peer-reviewed article about the drug. They didn’t get their wish. Now, documents released by the FDA via a lawsuit shed light on the attempt — and show how tricky it can be to correct the official record.

The controversy surrounds the approval of eteplirsen, a drug approved last September to treat Duchenne Muscular Dystrophy, a rare but invariably fatal disease that strikes (mostly) young boys. Eteplirsen was approved over the objections of the FDA team that reviewed the drug, which determined that there was insufficient evidence to approve the drug.

But the controversy didn’t end within the walls of the FDA complex. Ellis Unger, who led the review team, believed that one of the principal studies of the drug, published in the Annals of Neurology, was “misleading” because it was based on “unreliable data.” So in early November, Unger, joined by the then-head of the FDA, Robert Califf, took the extremely rare move of writing to the editor of the journal to “urge that the paper be corrected or retracted….”

According to the documents, the authors of the Annals article did, in fact, agree to correct the article.

On November 9, 2016, Clifford Saper, Annals‘ editor in chief, wrote to Califf and Unger:

Continue reading Released FDA docs reveal details of agency’s (failed) attempt to retract paper

Journal knew about problems in a high-profile study before it came out — and did nothing for over a month

In June, Gene Emery, a journalist for Reuters Health, was assigned to write a story about an upcoming paper in the Journal of the American College of Cardiology, set to come off embargo and be released to the public in a few days. Pretty quickly, he noticed something seemed off.

Emery saw that the data presented in the tables of the paper — about awareness of the problem of heart disease among women and their doctors — didn’t seem to match the authors’ conclusions. For instance, on a scale of 1 to 5 rating preparedness to assess female patients’ risk (with 5 being the most prepared), 64% of doctors answered 4 or 5; but the paper said “only a minority” of doctors felt well-prepared (findings echoed in an accompanying press release). On Monday June 19, four days before the paper was set to publish, Emery told the corresponding author — C. Noel Bairey Merz, Medical Director of the Women’s Heart Center at Cedars-Sinai in Los Angeles — about the discrepancy; she told him to rely on the data in the table.

But the more Emery and his editors looked, the more problems they found with the paper. They alerted the journal hours before it was set to publish, hoping that was enough to halt the process. It wasn’t.

Continue reading Journal knew about problems in a high-profile study before it came out — and did nothing for over a month